Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Replimune (REPL) Shares Outstanding (Weighted Average) (2017 - 2025)

Replimune has reported Shares Outstanding (Weighted Average) over the past 9 years, most recently at $91.9 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $91.9 million for Q4 2025, up 10.03% from a year ago — trailing twelve months through Dec 2025 was $91.9 million (up 10.03% YoY), and the annual figure for FY2025 was $80.6 million, up 21.02%.
  • Shares Outstanding (Weighted Average) reached $91.9 million in Q4 2025 per REPL's latest filing, roughly flat from $91.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $91.9 million in Q3 2025 and bottomed at $46.2 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $66.4 million (2023), compared with a mean of $66.3 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) soared 34.99% in 2021 before it grew 4.25% in 2024.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $52.3 million in 2021, then rose by 6.3% to $55.6 million in 2022, then rose by 19.62% to $66.5 million in 2023, then rose by 25.5% to $83.5 million in 2024, then grew by 10.03% to $91.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for REPL at $91.9 million in Q4 2025, $91.9 million in Q3 2025, and $91.5 million in Q2 2025.